Max Neeman International
Pawan K has over a decade of experience in clinical research, currently serving as a Validation Associate at Max Neeman International since June 2009, where responsibilities include preparation of annotated Case Report Forms (CRFs) and validation guidelines. Prior to this role, Pawan K worked as a Clinical Research Coordinator at Escorts Goyal Heart Hospital from January 2009 to June 2009, managing site development and responsibilities associated with clinical research. Pawan K holds a Bachelor of Science degree from T John College, completed in 2010.
This person is not in any offices
Max Neeman International
Max Neeman International, Max India’s full service Clinical Research Organization is headquartered in Delhi, with its US offices in Research Triangle Park, NC. Max Neeman International has the backing of this $2.0 billion life sciences consortium, owning twelve hospitals and managing other healthcare businesses in life insurance and healthcare. Most of the major Pharma's have a presence in India – with most all, working with Max Neeman. In addition Max Neeman Group has supported 85 Biotech and Device firms. Having completed [forty five] successful sponsor and site audits, we are also the first India based CRO holding recently acquired ISO-9000 certification. In addition, ISO 27001 and ISO 14155. Max Neeman International is able to assist the pharmaceutical, biotech and device industry in all aspects of conducting clinical trials in India and worldwide. SERVICES: •Phase I-IV study management •Feasibility study and protocol design •Clinical development strategies •Project management •Site monitoring •Medical monitoring •Site management •Data management / EDC & Legacy data conversion •Statistical analysis and reporting •Regulatory services •Import/export licenses •Pharmacy and drug distribution services •Safety monitoring •Medical writing COMPANY HIGHLIGHTS: • Offices strategically placed throughout India, increasing recruitment, sustaining hospital relationships and attracting top talent. relationships with 900 ICH GCP trained investigators across 175 Sites.